Press Release | Bentham science’s latest book ‘Frontiers in Anti-Cancer Drug Discovery Volume 10’

 

This eBook is authored by Dr. Atta-ur-Rahman, published on June; this book is authored by Atta-ur-Rahman and M. Iqbal Choudhary; published on May 31, 2019. For Further Details, Please Visit : https://ebooks.benthamscience.com/book/9789811400711/

9789811400711-1.jpg

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The tenth volume of the series features chapters covering the following topics:

  • Challenges in the Management of Hepatoblastoma
  • The Emerging Role of Monocarboxylate Transporter-1 in Cancer
  • In-vitro Anti-Proliferative Assays and Techniques Used in Pre-Clinical Anti-Cancer Drug Discovery
  • Recent Advances in the Development of Mesoporous Anti-Cancer Drug Nanocarriers
  • Polyphenols and Cancer
  • Glioblastoma Multiforme
  • Cutting Edge Targeting Strategies Utilizing Nanotechnology in Breast Cancer Therapy
Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-bsl062019.php

Highlighted Article – Glioblastoma Multiforme, Diagnosis and Treatment– Current Medicinal Chemistry

CMC-Articles_24-42-Noam Asna

http://www.eurekaselect.com/152454/article

Editor’s Choice – “Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy”

Journal: Current Cancer Drug Targets

Author(s): Drew A. Spencer, Brenda M. Auffinger, Jason P. Murphy, Megan E. Muroski, Jian Qiao, Yureve Gorind, Maciej S. Lesniak

003

Abstract:

Background: Glioblastoma multiforme (GBM) continues to devastate patients and outfox investigators and clinicians despite the preponderance of research directed at its biology, pathogenesis and therapeutic advances. GBM routinely outlasts multidisciplinary treatment protocols, almost inevitably recurring in a yet more aggressive and resistant form with distinct genetic differences from the original tumor. Attempts to glean further insight into GBM point increasingly toward a subpopulation of cells with a stem-like phenotype. These cancer stem cells, similar to those now described in a variety of malignancies, are capable of tumorigenesis from a population of susceptible cells.

Conclusions: Glioma stem cells have thus become a prevalent focus in GBM research for their presumed role in development, maintenance and recurrence of tumors. Glioma stem cells infiltrate the white matter surrounding tumors and often evade resection. They are uniquely suited both biochemically and environmentally to resist the best therapy currently available, intrinsically and efficiently resistant to standard chemo- and radiotherapy. These stem cells create an extremely heterogenous tumor that to date has had an answer for every therapeutic question, with continued dismal patient survival. Targeting this population of glioma stem cells may hold the long-awaited key to durable therapeutic efficacy in GBM.

Read more here: http://www.eurekaselect.com/148386

 

%d bloggers like this: